Aura Biosciences Gets FDA Agreement Regarding Phase 3 Clinical Trial of Bel-Sar
By Stephen Nakrosis
Aura Biosciences on Monday said it received agreement from the U.S. Food and Drug Administration for the design and plan of a Phase 3 trial of belzupacap sarotalocan as a treatment for patients with early-stage choroidal melanoma.
The company said it received the agreement from the FDA for the CoMpass phase 3 clinical trial of belzupacap sarotalocan, or Bel-sar, under a special protocol assessment.
If successful, Aura said, the trial could address the objectives necessary to support the company's planned biologics license application submission for Bel-sar as a treatment for choroidal melanoma, which is a form of eye cancer.
Aura said it presented "positive Phase 2 safety and efficacy data of Bel-sar" at the American Academy of Ophthalmology meeting in San Francisco.
Also on Monday, Aura said preliminary data from a phase 1 trial in bladder cancer showed the first patient using a single dose of Bel-sar with light activation demonstrated a clinical complete response "demonstrated by absence of cancer cells on histopathology with evidence of extensive necrosis and immune activation."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 06, 2023 15:35 ET (20:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?